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OBJECTIVES The aim of this study was to assess matrix metallloproteinase-3 (MMP3) gene variation in
relation to the degree of coronary atherosclerosis and risk of myocardial infarction (MI) in
patients with coronary artery disease.
METHODS In this study, we systematically screened the promoter and coding regions for sequence
variants. All polymorphisms identified were analyzed in 1,240 individuals undergoing
coronary angiography. Functional analyses of the polymorphisms were carried out with the
use of report assays and electrophoretic mobility shift assays.
RESULTS Six novel polymorphisms were identified. The 6A/6A genotype was associated with greater
number of coronary arteries with significant stenosis (odds ratio [OR] 1.52, p  0.008),
whereas the 5A/5A and 5A/6A genotypes were associated with increased risk of MI (OR 2.02
and 1.78, p  0.016 and 0.032, respectively). A stepwise logistic regression analysis with all
polymorphisms taken into account showed that the effect of MI susceptibility was largely
attributed to the 5A/6A polymorphism. In a stepwise logistic regression analysis with all
haplotypes as independent variables, the most common haplotype (T-5A-A-A-G-A), and
two rare haplotypes, all containing the 5A allele, were associated with MI susceptibility.
Functional studies showed that the T-5A-A-A-G-A haplotype had a higher promoter
activity in macrophages.
CONCLUSIONS These data indicate that the effect of MMP3 gene variation is attributable to the 5A/6A
polymorphism and that individuals carrying the 6A/6A genotype may be predisposed to
developing atherosclerotic plaques with significant stenosis, whereas those carrying the 5A
allele may be predisposed to developing unstable plaques. (J Am Coll Cardiol 2003;41:
2130–7) © 2003 by the American College of Cardiology Foundation
Matrix proteins (collagen, proteoglycan, and elastin),
smooth muscle cells, macrophages, and lipids are the main
constituents of atheromas (1). However, the relative pro-
portions of these components vary, giving rise to two types
of lesion referred to as fibrotic plaque and lipid-rich plaque,
respectively (2,3). The former is rich in matrix proteins and
smooth muscle cells, whereas the latter is rich in lipids and
macrophages. Fibrotic plaques are associated with high-
grade arterial stenosis, whereas lipid-rich plaques are less
stenosing but prone to rupture (2,3). Coronary atheroscle-
rotic plaque rupture is the most common cause of myocar-
dial infarction (MI) (4). Pathologic studies have revealed a
significant patient-to-patient variability in plaque composi-
tion (3). For example, an autopsy study of 54 subjects with
coronary artery disease (CAD) showed that in 15% of the
subjects, all the plaques present were predominantly fibrous,
whereas in another 13% of patients, all plaques were of the
lipid type (5).
The amount of matrix proteins in atheromas is deter-
mined by the function of matrix protein synthesis over
degradation, and the latter is catalyzed by matrix metallo-
proteinases (MMPs) (2,6). It has been shown that lipid-rich
plaques express higher levels of MMPs than fibrotic plaques
(7). Among the MMPs that are expressed in atheromas is
MMP3 (also known as stromelysin), which has a broad
substrate specificity and can activate other enzymes in the
MMP family (8,9). Inactivating the MMP3 gene in apoli-
poprotein E (apoE) knockout mice increases the sizes of
atherosclerotic plaques and the amounts of lesional matrix
proteins (10). In humans, a naturally occurring sequence
variant in the MMP3 gene promoter has been identified.
This sequence variant arises from the insertion of an
adenine nucleotide at position 1612 relative to the start of
transcription, resulting in one allele having a run of five
adenine nucleotides (5A) and the other having six adenine
nucleotides (6A) (11). Our previous work indicated that the
5A allelic promoter has a higher transcriptional activity than
the 6A allelic promoter (11). Several studies have shown
that the 6A allele is associated with more rapid progression
of coronary atherosclerosis (12–14) and increased carotid
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intima-media thickness (15–17), suggesting that matrix
accumulation is enhanced in individuals carrying this tran-
scriptionally less active allele of the MMP3 gene. In
addition, a Japanese study showed that the transcriptionally
more active 5A allele was over-represented in a group of
patients with acute MI compared with healthy control
subjects (18).
In this study, we investigated whether the 5A/6A poly-
morphism and/or other sequence variants in the MMP3
gene influenced the extent of atherosclerosis and risk of MI
in patients with CAD. We scanned the promoter and
coding regions of the MMP3 gene for sequence variants and
analyzed the variants in a sample of 1,240 Caucasian
individuals undergoing coronary angiography. We then
performed in vitro experiments to assess the functional
significance of the genetic variants.
METHODS
Subjects. We recruited 1,240 consecutive Caucasian pa-
tients undergoing interventional or diagnostic coronary
angiography in the Southampton General Hospital. Among
the 1,240 subjects, 943 had significant stenosis (50%) in at
least one major epicardial coronary artery, and the remain-
ing 297 had no significant stenosis (50%). Coronary
angiograms were assessed by one consultant cardiologist.
We also recorded demographic and clinical data, including
age, gender, weight, height, occupation, smoking habit,
hyperlipidemia, hypertension, diabetes mellitus, previous
MI, and coronary heart disease in first-degree relatives. The
main characteristics of the subjects are summarized in Table
1. The group with MI had a higher percentage of smokers
than did the group without MI (p  0.016). There was no
significant difference between patients with and those with-
out MI in terms of age, gender, and prevalence of hyper-
cholesterolemia, hypertension, diabetes, and family history
of CAD. Patient recruitment was approved by the local
Ethics Committee, and all subjects gave written, informed
consent.
Sequence variant scanning. The bi-directional dideoxy
fingerprinting (bi-ddF) method (19) was utilized to search
for sequence variants in the MMP3 gene, including the
promoter (2.3 kb), all 10 exons, and the intron–exon
junctions. The nature and location of sequence variants
identified by bi-ddF were determined by DNA sequencing.
The assays were performed on genomic DNA samples from
20 unrelated Caucasian individuals (10 with early-onset MI
[45 years] and 10 healthy subjects). This sample size (40
chromosomes) provided 90% power to detect polymor-
phisms with a minor-allele frequency of 5% (20), on the
basis that genetic variants contributing to a common disease
in a large proportion of patients are likely to be common in
the population, and thus the principal target of this work
was common sequence variants.
Determination of genotypes. The subjects previously de-
scribed were genotyped for the1986 TC,1612 5A6A,
1346 AC, 709 AC, 376 GC, and 802 AG
polymorphisms. For each polymorphism, a sequence contain-
ing the polymorphic site was amplified by the polymerase
chain reaction (PCR), and the amplicon was digested with
an appropriate restriction endonuclease, which specifically
cleaved one of the two alleles. Because of the limited
amounts of DNA samples available to us, some of the
polymorphisms could not be genotyped for some of the
subjects.
Reporter assays. The MMP3 gene promoter region (from
2309 bp to54 bp relative to the transcriptional start site)
was amplified by PCR. The amplicon was inserted into a
promoterless vector (pGL3-Basic Vector, Promega,
Southampton, United Kingdom) containing a firefly lucif-
erase reporter gene. The resultant construct was mixed with
a plasmid (pRL-TK, Promega) containing a renilla lucif-
Abbreviations and Acronyms
apo  apolipoprotein
CAD  coronary artery disease
bi-ddF  bi-directional dideoxy fingerprinting
MI  myocardial infarction
MMP  matrix metalloproteinase
PCR  polymerase chain reaction
Table 1. Characteristics of Subjects
Patients
With >50%
Stenosis
Subjects
Without >50%
Stenosis
Age (yrs) 63.6  10.2 60.2  12.0
Gender
Male 692 (73.4%) 138 (46.5%)
Female 251 (26.6%) 159 (53.5%)
Smoking status
Current smokers 156 (16.5%) 46 (15.5%)
Ex-smokers 517 (54.8%) 128 (43.1%)
Nonsmokers 270 (28.6%) 123 (41.4%)
Hypercholesterolemia
Yes 741 (78.6%) 189 (63.6%)
No 202 (21.4%) 108 (36.4%)
Hypertension
Yes 344 (36.5%) 76 (25.6%)
No 599 (63.5%) 221 (74.4%)
Diabetes
Yes 113 (12.0%) 19 (6.4%)
No 830 (88.0%) 278 (93.6%)
Family history of coronary
artery disease
Yes 523 (55.5%) 117 (39.4%)
No 420 (44.5%) 180 (60.6%)
Number of coronary arteries
with 50% stenosis
One 298 (31.6%)
Two 246 (26.1%)
Three 399 (42.3%)
Myocardial infarction
Yes 133 (14.1%) 2 (1.5%)
No 810 (85.9%) 295 (99.3%)
Data are presented as the mean value  SD or number (%) of patients/subjects.
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erase gene under the control of a thymidine kinase promoter
and transfected into cultured macrophages by electropora-
tion. The transfectants were cultured with or without 1
mol/l phorbol 12-myristate 13-acetate for 24 h. The cells
were then lysed, and the activities of the firefly luciferase and
renilla luciferase in the lysates were measured with the use of
a Dual-Luciferase assay kit (Promega). The ratio of firefly
luciferase level to renilla luciferase level was used as a
measurement of the MMP3 gene promoter activity. At least
four independent experiments in duplicates were carried out
for each construct, and the mean values  SEM are
presented.
Electrophoretic mobility shift assays. With the use of a
method by Alksnis et al. (21), nuclear protein extracts were
prepared from cultured macrophages differentiated from
human monocytic U937 cells with 1 mol/l phorbol 12-
myristate 13-acetate and from cultured human monocytoid
MonoMac-6 cells. For each polymorphism, two double-
stranded 26-mer oligonucleotides corresponding to the two
alleles were used as probes and labeled with [32-P]-
adenosine triphosphate. The labeled probes were incubated
with the aforementioned nuclear protein extracts, followed
by nondenaturing polyacrylamide gel electrophoresis and
autoradiography. Three independent experiments were car-
ried out for each polymorphism.
Statistical analyses. The HWE program was used to test
whether the observed genotype distributions deviated from
the Hardy-Weinberg equilibrium. Linkage disequilibrium
between the polymorphisms and the association metric D
were analyzed with the use of the ASSOCIATE program
and according to Devlin and Risch (22). Haplotype fre-
quencies (Table 2) were estimated using the Haplotyper
program (23), which employs a bayesian algorithm. To
assess the effects of the genetic variants, the MMP3 gene
polymorphisms were first examined individually in relation
to the number of coronary arteries with 50% stenosis by
ordinal logistic regression analysis (Table 3) and in relation
to the risk of MI by binary logistic regression analyses
(Table 4). Subsequently, stepwise logistic regression analysis
with all genotypes and haplotypes, or with all haplotypes but
not genotypes, inputted as independent variables, was per-
formed to investigate which polymorphism(s) and haplo-
type(s) accounted for the association with MI susceptibility
(Table 5).
RESULTS
Identification of novel variants in the MMP3 gene.
Sequence variant scanning in the promoter region, coding
region, and intron–exon junctions of the MMP3 gene
identified a total of six novel sequence variants, in addition
to the previously reported 5A/6A polymorphism. All newly
identified variants were single nucleotide polymorphisms:
four located in the promoter region and the remainder in
the coding region (Fig. 1). The 1986C, 16126A,
1346C, 709G, 376C, 802G, and 814C alleles
were detected in six of the 10 healthy individuals and five of
the 10 MI patients subjected to the variant scanning. The
frequencies of haplotypes in a group of individuals without
significant coronary atherosclerosis are shown in Table 2.
There was a substantial linkage disequilibrium between the
polymorphisms, with the linkage disequilibrium metric D
being over 0.9 for all polymorphisms, except for the 709
AG polymorphism, which had a lower frequency of the
minor allele (0.2 vs. 0.4 for the minor allele of the other
polymorphisms).
Association of MMP3 gene variation with extent of
coronary atherosclerosis. Based on the finding from pre-
vious studies that progression of coronary atherosclerosis
was more rapid in individuals with the MMP3 gene 6A/6A
genotype (12–14), we hypothesized that variation in this
gene could influence the extent of coronary atherosclerosis
in CAD patients. To test this hypothesis, the polymor-
phisms in the MMP3 gene were analyzed in a cohort of
Caucasian individuals undergoing coronary angiography. In
those without a history of MI, the number of coronary
arteries with 50% stenosis increased with increasing fre-
quency of the 6A/6A genotype (odds ratio [OR] 1.52, p 
0.008) (Table 3). This association remained significant after
adjustment for classic risk factors. Analyses in male and
female subjects separately showed a consistent trend. No
statistically significant association was detected between the
other polymorphisms in the MMP3 gene and the extent of
Table 2. Haplotype Frequencies in Subjects Without Significant
Coronary Stenosis
Haplotype Frequency
T-6A-A-G-G-A 0.009259
T-6A-A-A-G-A 0.003704
T-5A-A-G-G-A 0.003704
T-5A-A-G-G-G 0.001852
T-5A-A-G-C-G 0.001852
T-5A-A-A-G-A 0.422222
T-5A-A-A-G-G 0.024074
T-5A-A-A-C-A 0.011111
T-5A-A-A-C-G 0.012963
T-5A-C-A-G-A 0.024074
T-5A-C-A-G-G 0.003704
T-5A-C-A-C-G 0.022222
C-6A-A-G-G-A 0.003704
C-6A-A-G-C-A 0.001852
C-6A-A-G-C-G 0.020370
C-6A-A-A-G-A 0.014815
C-6A-A-A-G-G 0.001852
C-6A-A-A-C-A 0.005556
C-6A-A-A-C-G 0.018519
C-6A-C-G-G-G 0.001852
C-6A-C-G-C-A 0.009259
C-6A-C-G-C-G 0.155556
C-6A-C-A-G-A 0.001852
C-6A-C-A-G-G 0.005556
C-5A-C-G-C-G 0.001852
C-5A-C-A-G-A 0.003704
C-5A-C-A-C-G 0.018519
C-6A-C-A-C-G 0.194444
Bold type indicates the most frequent haplotypes.
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coronary atherosclerosis. There was no significant associa-
tion between MMP3 genotype and the extent of coronary
atherosclerosis in patients with MI.
Association of MMP3 gene variation with risk of MI in
CAD patients. We then tested the hypothesis that varia-
tion in the MMP3 gene could influence the risk of MI in
CAD patients. Logistic regression analyses showed that in
patients with 50% stenosis in at least one coronary artery,
there was an association between the 1612 5A/6A poly-
morphism and risk of MI, with the 5A/5A genotype
conferring a twofold increase in MI risk (p  0.016) (Table
4). Individuals who were heterozygous for the 5A/6A
polymorphism had an intermediate risk (OR 1.78, p 
0.032). The association between this polymorphism and MI
risk remained significant after adjustment for classic risk
factors. A similar trend was observed when male and female
subjects were analyzed separately.
In addition, there were approaching statistically signifi-
cant differences in MI risk between the genotypes for the
1986 TC polymorphism, such that individuals with the
T/T genotype had 1.67-fold higher risk of MI compared
with those with the C/C genotype (p  0.089 after
adjustment for covariates), whereas heterozygous individu-
als had an intermediate risk (OR 1.57, p  0.096). There
Table 3. Relationship Between Matrix Metalloproteinase-3 Gene Polymorphisms and Number of Coronary Arteries With
50% Stenosis
Polymorphism Genotype
No. of Coronary Arteries With >50% Stenosis
Unadjusted OR
(95% CI), p Value
Adjusted OR*
(95% CI), p Value0 1 2 3
1986 TC C/C 54 (20.5%) 54 (22.2%) 40 (20.3%) 66 (24.2%) 1.24 (0.89–1.71), 0.198 1.27 (0.91–1.78), 0.150
C/T 133 (50.6%) 122 (50.2%) 110 (55.8%) 139 (50.9%) 1.15 (0.88–1.51), 0.305 1.15 (0.87–1.51), 0.321
T/T 76 (28.9%) 67 (27.6%) 47 (23.9%) 68 (24.9%) 1 1
1612 5A6A 6A/6A 56 (19.3%) 58 (22.6%) 47 (22.3%) 89 (28.5%) 1.52 (1.11–2.07), 0.008 1.53 (1.11–2.11), 0.009
5A/6A 151 (52.1%) 133 (51.8%) 115 (54.5%) 151 (48.4%) 1.13 (0.87–1.46), 0.374 1.08 (0.82–1.41), 0.564
5A/5A 83 (28.6%) 66 (25.7%) 49 (23.2%) 72 (23.1%) 1 1
1346 AC C/C 49 (21.1%) 50 (22.9%) 40 (23.4%) 45 (18.7%) 1.06 (0.75–1.48), 0.757 1.02 (0.72–1.45), 0.888
A/C 103 (44.4%) 107 (49.1%) 90 (52.6%) 124 (51.5%) 1.25 (0.94–1.66), 0.113 1.23 (0.92–1.64), 0.150
A/A 80 (34.5%) 61 (28.0%) 41 (24.0%) 72 (29.9%) 1 1
709 AG G/G 13 (4.5%) 8 (2.8%) 12 (5.0%) 19 (5.0%) 1.67 (0.82–1.67), 0.387 1.70 (0.81–1.67), 0.227
A/G 88 (30.6%) 96 (33.2%) 76 (31.8%) 136 (35.7%) 1.08 (0.80–1.45), 0.624 1.03 (0.81–1.45), 0.599
A/A 187 (64.9%) 185 (64.0%) 151 (63.2%) 226 (59.3%) 1 1
376 GC C/C 48 (22.4%) 45 (22.1%) 32 (20.3%) 56 (25.8%) 0.74 (0.43–1.26), 0.264 1.15 (0.74–1.79), 0.521
G/C 105 (49.1%) 101 (49.5%) 89 (56.3%) 103 (47.5%) 0.92 (0.53–1.58), 0.762 1.08 (0.64–1.37), 0.682
G/G 61 (28.5%) 58 (28.4%) 37 (23.4%) 58 (26.7%) 1 1
802 AG G/G 39 (21.9%) 41 (24.8%) 27 (21.4%) 47 (26.0%) 0.91 (0.62–1.35), 0.644 1.13 (0.75–1.69), 0.544
A/G 90 (50.6%) 85 (51.5%) 68 (54.0%) 85 (47.0%) 0.88 (0.62–1.24), 0.473 0.75 (0.50–1.14), 0.180
A/A 49 (27.5%) 39 (23.6%) 31 (24.6%) 49 (27.1%) 1 1
*Adjusted for age, gender, smoking, hypercholesterolemia, hypertension, diabetes, and family history of coronary heart disease.
CI  confidence interval; OR  odds ratio.
Table 4. Analyses of Individual Polymorphisms in Relation to MI
Polymorphism Genotype
Previous
MI Non-MI
Unadjusted OR
(95% CI), p Value
Adjusted OR*
(95% CI), p Value
1986 TC T/T 37 (28.2%) 182 (25.5%) 1.60 (0.91–2.92), 0.103 1.67 (0.92–3.01), 0.089
C/T 74 (56.5%) 371 (52.0%) 1.63 (0.94–2.70), 0.083 1.57 (0.92–2.68), 0.096
C/C 20 (15.3%) 160 (22.4%) 1 1
1612 5A6A 5A/5A 39 (29.5%) 187 (24.0%) 2.02 (1.14–3.60), 0.016 1.87 (1.04–3.36), 0.036
5A/6A 73 (55.3%) 399 (51.2%) 1.78 (1.05–3.00), 0.032 1.57 (0.92–2.68), 0.095
6A/6A 20 (15.2%) 194 (24.9%) 1 1
1346 AC A/A 40 (33.6%) 174 (27.6%) 1.32 (0.76–2.29), 0.330 1.49 (0.83–2.66), 0.176
A/C 58 (48.7%) 321 (51.0%) 1.16 (0.69–1.96), 0.567 1.16 (0.67–2.00), 0.579
C/C 21 (17.6%) 135 (21.4%) 1 1
709 AG A/A 87 (66.4%) 475 (61.1%) 1.25 (0.47–3.27), 0.656 1.16 (0.43–3.11), 0.755
A/G 39 (29.8%) 269 (34.6%) 0.99 (0.36–2.67), 0.978 0.94 (0.34–2.58), 0.903
G/G 5 (3.8%) 34 (4.4%) 1 1
376 GC G/G 35 (29.4%) 153 (26.3%) 1.52 (0.84–2.76), 0.168 1.55 (0.85–2.84), 0.151
G/C 64 (53.8%) 293 (50.6%) 1.45 (0.85–2.50), 0.177 1.46 (0.84–2.53), 0.171
C/C 20 (16.8%) 133 (23.0%) 1 1
802 AG A/A 33 (31.7%) 119 (25.2%) 1.52 (0.83–2.78), 0.176 1.49 (0.80–2.77), 0.199
A/G 50 (48.1%) 238 (50.4%) 1.15 (0.66–2.01), 0.622 1.12 (0.63–1.97), 0.692
G/G 21 (20.2%) 115 (24.4%) 1 1
*Adjusted for age, gender, smoking, hypercholesterolemia, hypertension, diabetes, and family history of coronary heart disease.
MI  myocardial infarction; other abbreviations as in Table 3.
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was no statistically significant association between MI risk
and the other polymorphisms in the MMP3 gene (Table 2).
Stepwise logistic regression analysis. To estimate which
variants and haplotypes largely accounted for the association
between the MMP3 gene and MI susceptibility, we per-
formed a stepwise logistic regression analysis with all geno-
types (based on individual polymorphisms) and haplotypes
(based on combinations of the alleles of the polymorphisms)
inputted as independent variables. In this analysis, only the
5A/6A polymorphism was significantly associated with MI
risk and remained in the equation (Table 5). We then
carried out a stepwise logistic regression with all haplotypes,
but not genotypes, inputted as independent variables. In this
analysis without genotype terms, three haplotypes were
associated with MI risk and remained in the equation
(Table 5). These haplotypes—T-5A-A-A-G-A, T-5A-A-
A-C-G, and C-5A-C-G-C-G—contained the 5A allele at
the 1612 site but either the major or minor allele at the
other polymorphic sites.
Differences in transcriptional activity between haplotypes.
Our previous work showed that the 5A allele had a higher
promoter activity than the 6A allele (11). In this study, we
carried out transient transfection experiments and reporter
assays to investigate whether the difference in promoter
activity remained when the other polymorphisms were
taken into account. In these experiments, the T-5A-A-A-
G-A haplotype (which was the most common haplotype
and was associated with increased MI risk) consistently
showed a higher promoter activity than the C-6A-C-G-
C-G haplotype. This difference was detected consistently in
two different macrophage cell lines (RAW264.7 and
MALU) and became more pronounced when these cells
were stimulated with phorbol 12-myristate 13-acetate, a
reagent that induces macrophage differentiation (Table 6).
Allele-specific binding of nuclear protein at polymorphic
sites of the MMP3 promoter gene. We previously showed
that the sequence surrounding the 1612 5A6A poly-
morphic site was a transcription factor binding site and that
compared with the 5A allele, the 6A allele had a higher
affinity with the transcription factor (11). In the present
study, we carried out electrophoretic mobility shift assays to
investigate whether the other polymorphisms in the MMP3
gene promoter also showed an allele-specific interaction
with transcription factors. These assays showed binding of a
nuclear protein with a higher affinity to the 1986 T allele
than to the 1986 C allele (Fig. 2). No differential binding
of transcription factor was detected for the other promoter
polymorphisms (1346 AC, 709 AG, or 376 GC;
data not shown).
Analysis of variants in the coding region. Both coding
region polymorphisms identified are located in exon 2 of the
MMP3 gene. Whereas the 814 AG polymorphism is a
synonymous substitution, the 659 AG polymorphism
results in a change from glutamic acid (Glu) to lysine (Lys)
at residue 45, which is located just after the first alpha
helix in the propeptide. The three-dimensional structure
of the propeptide indicates that the region containing
residue 45 is flexible. Thus, the change from glutamic acid
Table 5. Stepwise Logistic Regression Analyses of Matrix Metalloproteinase-3 Haplotypes in Relation to Previous
Myocardial Infarction
Variables Inputted as
Independent Variables
Variables Remaining in
Equation
Unadjusted OR
(95% CI), p Value
Adjusted OR*
(95% CI), p Value
Analysis 1 All genotypes and haplotypes 1612 5A6A genotype 1.46 (1.05–2.03), 0.021 1.48 (1.07–2.06), 0.018
Analysis 2 All haplotypes but not genotypes T-5A-A-A-G-A haplotype 1.36 (1.02–1.80), 0.033 1.36 (1.02–1.81), 0.035
T-5A-A-A-C-G haplotype 4.04 (1.29–12.67), 0.017 4.32 (1.34–13.8), 0.014
C-5A-C-G-C-G haplotype NS 8.32 (1.08–63.77), 0.041
*Adjusted for age, gender, smoking, hypercholesterolemia, hypertension, diabetes, and family history of coronary heart disease.
Abbreviations as in Table 3.
Figure 1. Schematic presentation of all polymorphisms identified in the matrix metalloproteinase-3 gene.
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(an acidic amino acid) to lysine (a basic amino acid) at this
residue could potentially alter its interaction with other
amino acids in this region and could have an effect on
MMP3 activation. However, clustal alignment revealed
that though most residues in this region were conserved
across species, the Glu45 residue was not. The amino acid
sequences in this region are YDL44E45KDVKQF in humans,
YNL44E45KDVKQF in rabbits, YGL44A45KDVKQF in
mice, and YGL44E45KDVKQF in rats. This suggests that the
Lys45Glu polymorphism is unlikely to have a significant
functional impact. We are currently seeking to address this
question with in vitro studies.
DISCUSSION
In this study, we showed that CAD patients carrying the
MMP3 gene 5A allele were at a higher risk of MI compared
with CAD patients not carrying the 5A allele. A previous
Japanese study showed that the 5A/5A and 5A/6A geno-
types were over-represented in patients with acute MI
compared with healthy control subjects (18). Because the
comparison in that Japanese study was between MI patients
and healthy control subjects, the difference in MMP3
genotype frequency between the two groups might arise
from an association between the MMP3 gene and suscep-
tibility of CAD or from an impact of the MMP3 gene on
stability of coronary atherosclerotic plaques. The results of
the present study provide an answer to this question. We
found that among CAD patients, the 5A/5A and 5A/6A
genotypes were over-represented in those with a history of
MI compared with those without such a history, indicating
an influence of these genotypes on atherosclerotic plaque
stability.
In this study, we also showed that individuals with the
6A/6A genotype had a greater extent of coronary athero-
sclerosis, compared with individuals with other genotypes.
This finding is consistent with the finding from several
previous studies that the 6A/6A genotype is associated with
more rapid progression of coronary atherosclerosis (12–14)
and with greater intima-media thickness (15–17).
These findings support the notion that matrix accumu-
lation in the arterial wall is enhanced in individuals carrying
Table 6. Reporter Assays
Cell Condition Haplotype Luciferase Activity*
p Value by t Test
(5A vs. 6A)
RAW264.7 Unstimulated T-5A-A-A-G-A 30.30  3.81 (n  10) 0.030
C-6A-C-G-C-G 27.90  3.70 (n  10)
PMA stimulated T-5A-A-A-G-A 52.02  5.91 (n  10) 0.031
C-6A-C-G-C-G 42.70  4.83 (n  10)
MALU Unstimulated T-5A-A-A-G-A 16.94  0.87 (n  7) 0.018
C-6A-C-G-C-G 14.57  1.25 (n  7)
PMA stimulated T-5A-A-A-G-A 29.58  1.56 (n  4) 0.080
C-6A-C-G-C-G 24.75  1.50 (n  4)
*Mean  SEM (number of experiments).
PMA  phorbol 12-myristate 13-acetate.
Figure 2. Results of electrophoretic mobility shift assays. Two double-
stranded oligonucleotide probes corresponding to the T and C alleles,
respectively, of the 1986 TC polymorphism were labeled with 32P and
incubated with nuclear extracts from macrophages (U937 [a] and
MonoMac-6 [b]), followed by polyacrylamide gel electrophoresis and
autoradiography. The arrow indicates a DNA–protein complex that is
more readily detectable with the T probe (lanes 2 and 5) than the C probe
(lanes 4 and 9). The DNA–protein complex is readily competed with
unlabeled T probe (lanes 6 and 10), weakly competed with unlabeled C probe
(lanes 7 and 11), but not affected by a nonspecific competitor (lanes 8 and 12).
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the transcriptionally less active 6A allele of the MMP3
gene, whereas matrix degradation and atherosclerotic plaque
instability are increased in individuals carrying the transcrip-
tionally more active 5A allele. It is likely that individuals
carrying the 6A allele are predisposed to the development of
fibrotic plaques, which characteristically cause higher grade
stenosis, whereas those carrying the 5A allele are susceptible
to the development of lipid-rich plaques, which are typically
more prone to rupture, causing MI (3). For both the extent
of coronary atherosclerosis and risk of MI, individuals who
are heterozygous for the 5A/6A polymorphism have phe-
notypes similar to those carrying the 5A/5A genotype,
suggesting that the effect of the 5A allele is dominant and
that of the 6A allele is recessive.
It has been shown that atherosclerotic lesions are signif-
icantly smaller and contain significantly less collagen in
apoE//MMP3/ mice than in apoE//MMP3/
mice (10). In addition, atherosclerotic lesions in apoE//
MMP3/ mice have a higher content of lipids and
macrophages than those lesions in apoE//MMP3/
mice (10). These findings suggest that atherosclerotic
plaques in mice with an active MMP3 gene are the
lipid-rich type, whereas those in mice lacking the active
MMP3 gene are more fibrotic, which is consistent with the
findings of the present study of variation in the MMP3 gene
in humans.
Among the seven polymorphisms in the MMP3 gene,
only the 5A/6A polymorphism was found to have signifi-
cant effects on the extent of coronary atherosclerosis and MI
risk, although the 1986 TC polymorphism might also
exert a moderate influence. We have previously shown that
the 5A allelic promoter had a higher transcriptional activity
than the 6A allelic promoter (11). The present study
showed that this allelic difference in promoter activity
remained when the newly identified polymorphisms were
taken into account. The functional analyses of the 5A/6A
polymorphism in the previous study were carried out in
vascular smooth muscle cells and fibroblasts (11). Because
the majority of MMP3 in atherosclerotic plaques is pro-
duced by macrophages (8,9), this cell type was chosen for
the functional analyses in the present study. The results
showed that the effect of the MMP3 gene polymorphism on
promoter activity also exists in macrophages.
Previous work has shown that the a 26-bp sequence
containing the 5A/6A polymorphic site interacted with a
transcription factor that had a higher affinity with the 6A
allele than the 5A allele (11,24). In the present study, we
found that differential nuclear protein binding also occurred
on the sequence containing the 1986 TC polymorphic
site, with a nuclear protein interacting more readily with the
T allele. Because the two polymorphisms are in almost
complete linkage disequilibrium, the differential binding of
the nuclear protein to the 1986 TC polymorphism
might also contribute to the difference in promoter activity
between the T-5A-A-A-G-A and C-6A-C-G-C-G hap-
lotypes.
Conclusions. The data in this study indicate that variation
in the MMP3 gene influences the extent of coronary
atherosclerosis and risk of MI in patients with CAD. These
influences are largely attributable to the 5A/6A polymor-
phism, with the 6A/6A genotype being associated with the
extent of atherosclerosis and the 5A allele-containing geno-
types being associated with the risk of MI. These findings
suggest that the 5A/6A polymorphism may contribute to
the patient-to-patient variability in atherosclerotic plaque
composition (3,5).
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